Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 1076 of 6351
-
New stent aims to save lives from aortic tear
Disease control OngoingThis clinical trial is a prospective, multicenter, non-blinded, non-randomized study designed to assess the RelayPro thoracic endografts in the treatment of acute, complicated type B aortic dissection. The primary endpoint will measure all-cause mortality at 30 days post-procedur…
Sponsor: Bolton Medical • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Pairing a steroid with lymphoma gel may prevent painful skin reactions
Disease control CompletedThis is a two-arm, open-label study that aims to compare the incidence and severity of the most common adverse reactions, particularly contact dermatitis, when Valchlor is used alone or in conjunction with triamcinolone ointment 0.1% in early stage MF subjects (Stage IA and IB) f…
Phase 2 • Sponsor: Rochester Skin Lymphoma Medical Group, PLLC • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Breast cancer radiation cut to just 9 days in new trial
Disease control CompletedThis phase II trial studies how well hypofractionated radiation therapy works in treating patients with stage 0-IIB breast cancer. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fe…
Phase 2 • Sponsor: University of Utah • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New drug combo aims to stop breast cancer from coming back
Disease control OngoingThis research study is studying a drug as a possible treatment for ER-positive Breast Cancer The drug involved in this study is: -Ribociclib
Phase 2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Growth drug shows promise for kids with dwarfism
Disease control OngoingThe intent and design of this Phase 3 study is to assess BMN 111 as a therapeutic option for the treatment of children with Achondroplasia
Phase 3 • Sponsor: BioMarin Pharmaceutical • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Can tiny electrodes give amputees a better grip on bionic limbs?
Symptom relief Recruiting nowThe device, a bipolar percutaneous intramuscular electromyography electrode, is intended for use in upper-limb amputation patients who have received the regenerative peripheral nerve interface surgical procedure, in order to enable the use of advanced prosthetic arms and hands.
Sponsor: University of Michigan • Aim: Symptom relief
Last updated Aug 20, 2026 00:00 UTC
-
Speedier lab test could curb superbug threat in ICU pneumonia
Diagnosis CompletedInappropriate antibiotic therapy in ventilator-associated pneumonia (VAP) is associated with increased mortality. The international guidelines recommend using broad spectrum antimicrobials especially in patients who received previous antimicrobials, with risk factors of muti-drug…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Diagnosis
Last updated Aug 14, 2026 00:00 UTC
-
Less oxygen may save more lives after cardiac arrest, study hints
Disease control Stopped earlyThe Reduction of oxygen after cardiac arrest (EXACT) is a multi-centre, randomised, controlled trial (RCT) to determine whether reducing oxygen administration to target an oxygen saturation of 90-94%, compared to 98-100%, as soon as possible following successful resuscitation fro…
Sponsor: Monash University • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Two-Drug combo aims to outsmart recurrent brain tumors
Disease control OngoingThis randomized phase II trial studies how well cediranib maleate and olaparib work compared to bevacizumab in treating patients with glioblastoma that has come back (recurrent). Cediranib maleate and olaparib may stop the growth of tumor cells by blocking some of the enzymes nee…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Two-Drug cocktail shows promise against tough liver cancer
Disease control CompletedThis phase Ib/II trial studies how well sorafenib tosylate and pembrolizumab work in treating patients with liver cancer that has spread to other parts of the body. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoc…
Phase 1/2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New drug duo takes on kidney cancer in major trial
Disease control CompletedThe purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat compared to sunitinib or pazopanib in participants with locally advanced/metastatic renal cell carcinoma (mRCC) with a clear cell component who have not received prior systemic the…
Phase 3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Brain cancer vaccine trial halted: what we know
Vaccine Stopped earlyThe purpose of this study is to assess the safety and tolerability of VBI-1901 in subjects with recurrent malignant gliomas (glioblastoma, or GBM).
Phase 1/2 • Sponsor: VBI Vaccines Inc. • Aim: Vaccine
Last updated Jun 27, 2026 12:30 UTC
-
New psoriasis drug shows promise in major trial
Disease control CompletedThis is a study to compare the efficacy of bimekizumab versus placebo and an active comparator in the treatment of subjects with moderate to severe chronic plaque psoriasis (PSO).
Phase 3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Gene therapy trial aims to slow duchenne muscular dystrophy in boys
Disease control OngoingThis is a controlled, open-label, single-ascending dose study to evaluate the safety and tolerability of SGT-001 in adolescents and children with Duchenne muscular dystrophy (DMD). Participants will receive a single intravenous (IV) infusion of SGT-001 and will be followed for ap…
Phase 1/2 • Sponsor: Solid Biosciences Inc. • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Zap away tremors: new radiation technique offers hope for patients unsuitable for surgery
Disease control OngoingTo determine the efficacy of frameless Virtual Cone Radiosurgical Thalamotomy for medically refractory tremor resulting from either Essential Tremor or Tremor-Dominant Parkinson's Disease with the Fahn-Tolosa-Marin Tremor Rating Scale (FTMTRS) in patients who are not candidates f…
Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New combo therapy aims to keep early lung cancer from returning
Disease control CompletedThis is a randomized multicentre open label phase II study of Durvalumab following Stereotactic Body Radiotherapy (SBRT) in patients with T1-2N0M0 NSCLC. Patients will be randomized 1:1 to follow up or receiving Durvalumab every 4th week for 12 months
Phase 2 • Sponsor: Vastra Gotaland Region • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New drug combo shows promise in head and neck cancer battle
Disease control CompletedThe purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat, pembrolizumab monotherapy, and the EXTREME regimen (cetuximab + cisplatin or carboplatin + 5-fluorouracil) as first-line treatment for recurrent or metastatic head and neck squamo…
Phase 3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Immune cells injected into brain show promise against deadly cancer
Disease control Recruiting nowThe main objective of this clinical study is to evaluate the safety and tolerability of NK-92/5.28.z and to determine the maximum tolerated dose or maximum feasible dose (MFD). Recommended phase 2 doses both for intraoperative injections only (RP2Diio) and repetitive injections (…
Phase 1 • Sponsor: Johann Wolfgang Goethe University Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Robot suit aims to get paralyzed patients back on their feet
Disease control OngoingBackground and Rationale: Traumatic spinal cord injury (SCI) affects approximately 12,400 individuals annually in the USA, predominantly impacting healthy young adults aged 20-40 years. Complete SCI above the lumbar region results in paraplegia or tetraplegia, severely compromis…
Sponsor: University of Pecs • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Patient choice in prostate cancer: two pills, one preference
Disease control CompletedTo assess patient preference between ODM-201 and enzalutamide by patient preference questionnaire
Phase 2 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC